These eight monoclonal antibodies help detect four high molecular weight glycoproteins — CA 15-3, CA 19-9, CA 125, and CA 72.4 — to aid in the diagnosis and monitoring of malignant tumors.
These antibodies are relatively tumor specific with CA 15-3 for breast cancer, CA 19-9 for colorectal cancer and pancreatic cancer, CA 125 for non-mucinous ovarian cancer, and CA 72.4 for a variety of human adenocarcinomas.
The company has two monoclonal antibodies against Cancer Antigen 15-3 (DF3 Antigen) that are specific for an epitope localized on two distinct mucin-like glycoproteins (330- kD and 450kD) found in human breast cancer.
Two monoclonal antibodies against Cancer Antigen 19-9 react with a carbohydrate antigenic determinant detected in most adenocarcinomas of the pancreas, stomach, colon and gall bladder.
Also offered are two monoclonal antibodies against Cancer Antigen 125 that are specific for an epitope present on high-molecular weight, mucin-like glycoprotein. The serum level of CA 125 has been shown to rise with the progression of metastatic ovarian tumor.
Keyword: cancer, antibody